Department of Medical Oncology, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
Department of Clinical Laboratory, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
Cancer Immunol Immunother. 2023 Oct;72(10):3259-3277. doi: 10.1007/s00262-023-03485-5. Epub 2023 Jul 17.
Antigen-presenting cells (APC)/T/NK cells are key immune cells that play crucial roles in fighting against malignancies including lung adenocarcinoma (LUAD). In this study, we aimed to identify an APC/T/NK cells-related gene signature (ATNKGS) and potential immune cell-related genes (IRGs) to realize risk stratification, prognosis, and immunotherapeutic response prediction for LUAD patients.
Based on the univariate Cox regression and the LASSO Cox regression results of 196 APC/T/NK cells-related genes collected from three pathways in the KEGG database, we determined the final genes and established the ATNKGS-related risk model. The single-cell RNA sequencing data were applied for key IRGs identification and investigate their value in immunotherapeutic response prediction. Several GEO datasets and an external immunotherapy cohort from Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, were applied for validation.
In this study, nine independent public datasets including 1108 patients were enrolled. An ATNKGS containing 16 genes for predicting overall survival of LUAD patients was constructed with robust prognostic capability. The ATNKGS high risk group was related to significantly worse OS outcomes than those in the low-risk group, which were verified in TCGA and four GEO datatsets. A nomogram combining the ATNKGS risk score with clinical TNM stage achieved the optimal prediction performance. The single-cell RNA sequencing analysis revealed CTSL as an IRG of macrophage and monocyte. Moreover, though CTSL was an indicator for poor prognosis of LUAD patients, CTSL high expression group was associated with higher ESTIMATEScore, immune checkpoints expression, and lower TIDE score. Several immunotherapeutic cohorts have confirmed the response-predicting significance of CTSL in patients receiving immune checkpoint inhibitor (ICI) treatment.
Our study provided an insight into the significant role of APC/T/NK cells-related genes in survival risk stratification and CTSL in response prediction of immunotherapy in patients with LUAD.
抗原呈递细胞(APC)/T/NK 细胞是关键的免疫细胞,在对抗包括肺腺癌(LUAD)在内的恶性肿瘤中发挥着至关重要的作用。在这项研究中,我们旨在确定一个 APC/T/NK 细胞相关基因特征(ATNKGS)和潜在的免疫细胞相关基因(IRGs),以实现 LUAD 患者的风险分层、预后和免疫治疗反应预测。
基于从 KEGG 数据库中三个途径收集的 196 个 APC/T/NK 细胞相关基因的单变量 Cox 回归和 LASSO Cox 回归结果,我们确定了最终基因并建立了 ATNKGS 相关风险模型。单细胞 RNA 测序数据被应用于关键 IRGs 的鉴定,并研究其在免疫治疗反应预测中的价值。几个 GEO 数据集和来自中国医学科学院肿瘤医院和北京协和医学院的一个外部免疫治疗队列被用于验证。
在这项研究中,纳入了 9 个包含 1108 名患者的独立公共数据集。构建了一个包含 16 个基因的 ATNKGS,用于预测 LUAD 患者的总体生存率,具有稳健的预后能力。ATNKGS 高风险组的 OS 结果明显差于低风险组,这在 TCGA 和四个 GEO 数据集得到了验证。结合 ATNKGS 风险评分和临床 TNM 分期的列线图达到了最佳的预测性能。单细胞 RNA 测序分析显示 CTSL 是巨噬细胞和单核细胞的 IRG。此外,尽管 CTSL 是 LUAD 患者预后不良的指标,但 CTSL 高表达组与更高的 ESTIMATEScore、免疫检查点表达和更低的 TIDE 评分相关。几个免疫治疗队列已经证实了 CTSL 在接受免疫检查点抑制剂(ICI)治疗的患者中的反应预测意义。
我们的研究深入了解了 APC/T/NK 细胞相关基因在生存风险分层中的重要作用,以及 CTSL 在 LUAD 患者免疫治疗反应预测中的作用。